ARDS vs. ARAV, BCEL, SXTP, PHIO, NBY, REVB, AGRX, RNAZ, ONCO, and CWBR
Should you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Aravive (ARAV), Atreca (BCEL), 60 Degrees Pharmaceuticals (SXTP), Phio Pharmaceuticals (PHIO), NovaBay Pharmaceuticals (NBY), Revelation Biosciences (REVB), Agile Therapeutics (AGRX), TransCode Therapeutics (RNAZ), Onconetix (ONCO), and CohBar (CWBR). These companies are all part of the "pharmaceutical preparations" industry.
Aridis Pharmaceuticals (NASDAQ:ARDS) and Aravive (NASDAQ:ARAV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.
Aridis Pharmaceuticals currently has a consensus price target of $2.00, suggesting a potential upside of 2,976.92%. Aravive has a consensus price target of $13.50, suggesting a potential upside of 33,565.84%. Given Aravive's higher probable upside, analysts plainly believe Aravive is more favorable than Aridis Pharmaceuticals.
Aridis Pharmaceuticals has a net margin of -5.11% compared to Aravive's net margin of -569.65%.
Aridis Pharmaceuticals received 18 more outperform votes than Aravive when rated by MarketBeat users. However, 62.28% of users gave Aravive an outperform vote while only 61.00% of users gave Aridis Pharmaceuticals an outperform vote.
Aridis Pharmaceuticals has higher earnings, but lower revenue than Aravive. Aridis Pharmaceuticals is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.
9.7% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 35.8% of Aravive shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Aridis Pharmaceuticals has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Aravive has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500.
In the previous week, Aravive had 1 more articles in the media than Aridis Pharmaceuticals. MarketBeat recorded 1 mentions for Aravive and 0 mentions for Aridis Pharmaceuticals. Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.
Summary
Aridis Pharmaceuticals and Aravive tied by winning 8 of the 16 factors compared between the two stocks.
Get Aridis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aridis Pharmaceuticals Competitors List
Related Companies and Tools
